Applied UV Enters Three Year Agreement Through its Scandinavian Distribution Partner Airocide Nordic Oy with Plandent Division for Distribution of Airocide(R) to Dental Providers
Applied UV (NASDAQCM: AUVI) announces a three-year agreement with Plandent Division for the distribution of Airocide® air purification systems in the dental community, starting in Finland and expanding throughout Scandinavia and Europe. With an estimated 21,500 dental practices in Scandinavia, this partnership aims to enhance air quality and protect staff and patients from airborne pathogens, especially in light of recent health concerns like COVID-19. Max Munn, President and Interim CEO, emphasized the significance of improved air quality in dental environments.
- Secured a three-year distribution agreement with Plandent Division, a major player in the dental market.
- Potential access to approximately 21,500 dental practices across Scandinavia, representing a significant market opportunity.
- The Airocide® technology enhances air quality and safety in dental practices, addressing recent health threats.
- None.
Covers Finland with plans to expand throughout all of countries in Scandinavia and Europe
MOUNT VERNON, NY / ACCESSWIRE / February 22, 2022 / Applied UV, Inc. (NASDAQCM:AUVI) ("Applied UV" or the "Company"), a pathogen elimination technology company that applies the power of narrow-range ultraviolet light ("UVC") for surface areas and catalytic bioconversion technology for air purification to destroy pathogens safely, thoroughly, and automatically announces that it's Scandinavian distributor Airocide Nordic Oy has entered into a three-year agreement with Plandent Division for distribution of its patented Airocide® commercial air purification systems to the professional dental community launching initially in Finland, expanding distribution to include all of the countries in Scandinavia and plans to broaden expansion throughout all of Europe.
Headquartered in Helsinki, Finland, Plandent Division is a wholly-owned entity of Planmeca Oy, the 3rd largest supplier to the dental industry in Europe. The company operates throughout Europe supplying a wide range of quality-driven, modern dental products and solutions.
"We estimate there are approximately 21,500 dental practices throughout Scandinavia, representing a significant market opportunity for our products," stated Max Munn, President and Interim CEO. "Plandent is a recognized leader for the supply of dental products and equipment and an ideal partner to expand our footprint and helps us capture a meaningful share of the Scandinavian market. In healthcare environments, air quality is perhaps the most easily forgotten component of microbial burden. The constant traffic of patients and staff combined with the effect of ongoing procedures ensures consistently high levels of airborne microbial contamination. Chemicals used in cleaning and sterilization can also contribute to significant levels of VOCs in the air. Implementing the Airocide® air disinfection technology, which constantly works at the point of care, results in increased safety of the environment and the wellbeing of patients and staff."
Mr. Munn continued, "Recent health threats and the possibility of contracting a potentially life-threatening virus such as COVID-19 has increased the dental community's pursuit of solutions that can reduce aerosols and splatter and provide clean air quality. Research published in the Journal of Dentistry in February 2021, confirmed that if a room's ventilation rate is low, respiratory aerosol particles can remain in the indoor air for a long time, making it critical to remove respiratory aerosol to minimize potential exposures of airborne viruses to patients and providers. Creating clean air quality in dental offices is not possible solely with the use of high suction and a central air conditioning system. Improved ventilation and air filtration are important steps in a multi-layered approach for safe delivery of dental care. By installing the patented Airocide® System, both staff and patients will have additional protection."
About Plandent Division
Plandent Division is part of the Planmeca Group, whose parent company Planmeca Oy is the largest privately-owned company in the dental sector. Planmeca Oy, the third largest dental equipment manufacturer in Europe, designs and manufactures advanced dental equipment and x-ray units, software products and imaging solutions. Planmeca exports 98 percent of its production to over 120 countries through 550 distributors. Headquartered in Helsinki, Finland, the Plandent Division operates in nearly 15 countries throughout Europe. Plandent Division's business units supply a wide range of quality-driven, modern dental products and solutions. Since its founding in 1972, Plandent Division has become one of the most influential dental suppliers in Europe. For more information, please visit https://www.planmeca.com/company/planmeca-group/ or https://www.plandent.com/.
About Applied UV
Applied UV is focused on the development and acquisition of technology that address infection control in the healthcare, hospitality, commercial and municipal markets. The Company has two wholly owned subsidiaries - SteriLumen, Inc. ("SteriLumen") and Munn Works, LLC ("Munn Works"). SteriLumen's connected platform for Data Driven Disinfection™ applies the power of ultraviolet light (UVC) to destroy pathogens safely, thoroughly, and automatically, addressing the challenge of healthcare-acquired infections ("HAIs"). Targeted for use in facilities that have high customer turnover such as hospitals, hotels, commercial facilities, and other public spaces, the Company's Lumicide™ platform uses UVC LEDs in several patented designs for infection control in and around high-traffic areas, including sinks and restrooms, killing bacteria, viruses, and other pathogens residing on hard surfaces within devices' proximity. The Company's patented in-drain disinfection device, Lumicide Drain, is the only product on the market that addresses this critical pathogen intensive location. SteriLumen's Airocide® air purification devices are research backed, clinically proven and developed for NASA with assistance from the University of Wisconsin. Airocide® is listed as an FDA Class II Medical device, utilizes a proprietary photo-catalytic (PCO) bioconversion technology that draws air into a reaction chamber that converts damaging molds, microorganisms, dangerous airborne pathogens, destructive VOCs, allergens, odors and biological gasses into harmless water vapor and green carbon dioxide without producing ozone or other harmful byproducts. Airocide® applications include healthcare, hospitality, grocery chains, wine making facilities, commercial real estate, schools, dental offices, post-harvest, grocery and homes. For more information about Applied UV, Inc., and its subsidiaries, please visit the following websites: https://www.applieduvinc.com/; https://sterilumen.com/; https://www.airocide.com https://kesscience.com; https://scientificairmanagement.com and, https://munnworks.com/.
Forward-Looking Statements
The information contained herein may contain "forward‐looking statements." Forward‐looking statements reflect the current view about future events. When used in this press release, the words "anticipate," "believe," "estimate," "expect," "future," "intend," "plan," or the negative of these terms and similar expressions, as they relate to us or our management, identify forward‐looking statements. Such statements include, but are not limited to, statements contained in this press release relating to the view of management of Applied UV concerning its business strategy, future operating results and liquidity and capital resources outlook. Forward‐looking statements are based on the Company's current expectations and assumptions regarding its business, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. The Company's actual results may differ materially from those contemplated by the forward‐looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. We caution you therefore against relying on any of these forward‐looking statements. Factors or events that could cause the Company's actual results to differ may emerge from time to time, and it is not possible for the Company to predict all of them. The Company cannot guarantee future results, levels of activity, performance, or achievements. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward‐looking statements to conform these statements to actual results.
For additional Company Information:
Applied UV Inc.
Max Munn
Applied UV Interim CEO
max.munn@sterilumen.com
Contact:
Brett Maas, Managing Principal
Hayden IR
brett@haydenir.com
(646) 536-7331
SOURCE: Applied UV, Inc.
View source version on accesswire.com:
https://www.accesswire.com/689671/Applied-UV-Enters-Three-Year-Agreement-Through-its-Scandinavian-Distribution-Partner-Airocide-Nordic-Oywith-Plandent-Division-for-Distribution-of-AirocideR-to-Dental-Providers
FAQ
What is the recent agreement announced by Applied UV (AUVI)?
Which markets will Applied UV expand into with the new distribution agreement?
How many dental practices are estimated to be in Scandinavia?
What health concerns does Airocide® address in dental environments?
Who is the interim CEO of Applied UV (AUVI)?
